gallic acid has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies
gallate : A trihydroxybenzoate that is the conjugate base of gallic acid.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chandramohan Reddy, T | 1 |
| Bharat Reddy, D | 1 |
| Aparna, A | 1 |
| Arunasree, KM | 1 |
| Gupta, G | 1 |
| Achari, C | 1 |
| Reddy, GV | 1 |
| Lakshmipathi, V | 1 |
| Subramanyam, A | 1 |
| Reddanna, P | 1 |
1 other study available for gallic acid and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Anti-leukemic effects of gallic acid on human leukemia K562 cells: downregulation of COX-2, inhibition of BCR/ABL kinase and NF-κB inactivation.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cyclooxygenase 2; Dose-Response Relationship, Drug; Do | 2012 |